ROP

Study explores ranibizumab as treatment for ROPIntravitreal ranibizumab (Lucentis, Genentech) appears to be effective for treatment of severe retinopathy of prematurity (ROP) and associated with less persistent suppression of systemic VEGF compared with bevacizumab (Avastin, Genentech), according to research reported by Shunji Kusaka, MD.
Systemic safety of anti-VEGF treatment for ROP mandates further study
Systemic safety of anti-VEGF treatment for ROP mandates further studyAccumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Treating ROP: Laser associated with high success rate for retinopathy of prematurityLaser photocoagulation is a time-tested, well-defined, and effective treatment for retinopathy of prematurity (ROP) with requirements for follow-up that are much more manageable compared with anti-vascular endothelial growth factor (anti-VEGF) therapy, argued David K. Wallace, MD, MPH.
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I disease
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I diseaseAnti-VEGF therapy for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD.
Ethics involved in using anti-VEGFs for pediatric patientsParents must be given a full understanding of the treatment risks and potential alternatives in pediatric ROP cases.
Imaging, 27-gauge systems capture retina surgeons’ focusRetina surgeons considered 2015 to be an exciting time in the subspecialty in all areas and pointed to the availability and increased use of 27-gauge instrumentation as one of the real highlights of surgical retina.
Year brings advances in retinal imaging, screening, and gene/drug therapiesThe topics of special interest to retina specialists during 2015 include optical coherence tomography angiography (OCTA) and screening for retinopathy of prematurity (ROP). Important research is taking place to determine the etiology of angiogenesis, possibly leading to targeting therapies in age-related macular degeneration (AMD), ROP, and diabetic retinopathy.
DRCR.net retinal treatment results take center stage in 2015Studies of the efficacy of anti-vascular endothelial growth factor (VEGF), gene therapies, and slow-release drug delivery systems took center stage among treatments for retinal disorders in 2015. In addition to studies already under way, others are about to begin.
Identifying signs of congenital eye health problemsWhere does a visual impairment begin? Vision disorders can be influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. When taking these into account, beginning with proper prenatal care is a good place to start.
Intravitreal bevacizumab: Improved vascular pattern after treatment in ROPAfter intravitreal bevacizumab injection in eyes with treatment requiring-retinopathy of prematurity, there was growth and maturation of retinal vessels, although certain abnormalities remained.